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offered by gene knockout technologies in mice. Unfortunately, 
germline knockouts can not address the speciﬁ  c serotonergic func-
tion of widely expressed genes without affecting the gene in other 
tissues as well. Moreover, germline gene inactivation may result in a 
lethal phenotype or induction of compensatory, homeostatic mech-
anisms or pleiotropy during development. Therefore, delineation 
of the particular function of the serotonergic system in relationship 
to other neuronal systems as well as the exact developmental and 
adult role of genes in 5-HT neurons remains elusive.
To overcome these obstacles, we have developed a CreERT2/
loxP-recombination system that allows temporal control of 
conditional gene manipulation speciﬁ  cally in serotonergic neu-
rons. Temporal control of recombination is a prerequisite for 
  distinguishing the developmental role of a gene from its present 
function during adulthood. For that reason, we took advantage 
of a fusion protein consisting of Cre recombinase and a mutated 
ligand- binding domain (LBD) of the human estrogen receptor (ER) 
that was developed to achieve tamoxifen dependent Cre activity 
(Feil et al., 1997; Indra et al., 1999).
We have chosen regulatory sequences of the tryptophan hydrox-
ylase 2 (Tph2) gene which is exclusively expressed in serotonergic 
neurons during development and adulthood (Cote et al., 2003, 
2007) to accurately direct Cre expression to 5-HT neurons of the 
brain. Transgenic TPH2-CreERT2 mice were generated by DNA 
microinjection of a modiﬁ  ed DNA construct containing the Tph2 
open reading frame together with large upstream and downstream 
INTRODUCTION
Serotonergic neurons receive multiple, modulatory inputs from 
the hypothalamic–pituitary–adrenal (HPA) axis (Harfstrand 
et al., 1986; Day et al., 2004) and glutamatergic, GABAergic and 
other monoaminergic neurons (Sodhi and Sanders-Bush, 2004). 
Conversely, serotonergic (5-HT) neurons project to most structures 
of the brain (Hensler, 2006).
Serotonergic neurons modulate physiological functions includ-
ing sleep, circadian rhythm, feeding, and neuroendocrine function 
(Hensler, 2006) as well as complex behaviors such as aggression 
(Miczek et al., 2007) or anxiety (Lucki, 1998). A multitude of evi-
dence points to serotonergic dysregulation during development 
and adulthood in the etiology of many psychiatric diseases (Caspi 
et al., 2003; Mann, 2003; Gordon and Hen, 2004; Zill et al., 2004; 
Carver and Miller, 2006; Miczek et al., 2007; Mossner et al., 2007; 
Oades, 2007; Pardo and Eberhart, 2007; Carver et al., 2008; Geyer 
and Vollenweider, 2008; Serretti and Mandelli, 2008).
Furthermore, 5-HT plays a key role during development, being 
an essential neurotransmitter for proper neuronal division, differ-
entiation, migration and synaptogenesis (Gaspar et al., 2003). Even 
transient alterations in serotonin homeostasis during development 
cause permanent changes to adult behavior (Ansorge et al., 2004; 
Gross and Hen, 2004).
In order to dissect the molecular basis of the multiplex seroton-
ergic involvement in a plethora of physiological and pathophysi-
ological brain functions, researchers have turned to the speciﬁ  city 
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ﬂ  anking regions (177 kb). Breeding to three different mouse lines 
with loxP-ﬂ  anked alleles shows reliable and efﬁ  cient serotonergic 
neuron speciﬁ  c induction of recombination following tamoxifen 
treatment during development and adulthood and so represents 
a new and powerful tool for conditional gene manipulation in the 
serotonergic system.
MATERIALS AND METHODS
GENERATION OF TPH2-CreERT2 TRANSGENIC MICE
A 196-kb PAC (RP24-243J21, RZPD, Deutsches Ressourcenzentrum 
für Genomforschung GmbH) that contains the full-length mouse 
Tph2 gene (107 kb) with 51 kb upstream and 19 kb downstream 
DNA sequences was selected for recombineering in EL250 bacte-
ria (Lee et al., 2001). First, the kanamycin resistance gene of the 
pPAC4-backbone was replaced with a chloramphenicol resistance. 
Next, a cassette encoding a fusion protein (CreERT2) consisting 
of a Cre-recombinase (Cre) and a mutated LBD of the human ER 
(ERT2) as well as a kanamycin resistance gene ﬂ  anked by two FRT 
sites was integrated into the ATG-start codon of the TPH2-gene. 
A 23-bp sequence downstream of the ATG-translation start of Tph2 
was intentionally deleted since it contained additional in-frame 
ATG-start sites in Exon 1 (Figure S1 in Supplementary Material). 
The FRT-ﬂ  anked kanamycin resistance cassette was then deleted by 
arabinose-induced expression of Flp recombinase. The CreERT2-
modiﬁ  ed genomic Tph2 sequence was separated from the PAC 
backbone by NotI digestion and subsequent preparative pulse-ﬁ  eld 
electrophoresis. The puriﬁ  ed, linearized DNA was microinjected into 
the pronucleus of C57BL/6N mouse oocytes. Transgenic offspring 
(founders) were identiﬁ  ed by PCR genotyping of tail DNA. TPH2-
CreERT2 transgenic mice were always crossed with C57BL/6N mice 
periodically purchased from Charles River Laboratories.
The TPH2-CreERT2-transgenic mice were bred with R26R 
(Soriano, 1999), Brainbow1.0L (Livet et  al., 2007) and GRﬂ  ox 
(Tronche et  al., 1999) mice to generate transgenic mice for 
recombination analysis: R26RTPH2-CreERT2, Brainbow1.0LTPH2-CreERT2, 
and GRﬂ  ox/GRﬂ  oxTPH2-CreERT2. To this purpose, TPH2-CreERT2 
mice were crossed with R26R and Brainbow mice to generate 
double transgenic R26RTPH2-CreERT2 and Brainbow1.0LTPH2-CreERT2 
mice,   respectively. To generate GRﬂ  ox/GRﬂ  oxTPH2-CreERT2 mice we 
ﬁ   rst crossed TPH2-CreERT2 mice with homozygous GRﬂ  ox/
GRﬂ  ox mice. GRﬂ  oxTPH2-CreERT2 mice were then crossed again with 
homozygous GRﬂ  ox/GRﬂ   ox mice to ﬁ  nally  generate  GRﬂ  ox/
GRﬂ  oxTPH2-CreERT2 mice.
IN VIVO INDUCTION OF Cre-MEDIATED RECOMBINATION 
WITH TAMOXIFEN
Tamoxifen (Sigma) was dissolved in a corn oil/ethanol (10:1) mix-
ture at a ﬁ  nal concentration of 10 mg/ml. Adult R26RTPH2-CreERT2 
and GRﬂ  ox/GRﬂ  oxTPH2-CreERT2 mice (8–12 weeks) were injected 
intraperitoneally twice daily for ﬁ  ve consecutive days (protocol 1) 
with 1 mg of tamoxifen. Adult Brainbow1.0LTPH2-CreERT2 mice (8–12 
weeks) were injected intraperitoneally twice daily for one to ﬁ  ve 
consecutive days. Control animals were injected with 100 µl of 
a corn oil/ethanol vehicle mixture (vehicle). Experimental ani-
mals for immunohistochemistry (IHC) or X-gal staining were 
sacriﬁ  ced 5–14 days after the last injection. For recombination 
analysis during embryogenesis, pregnant R26RTPH2-CreERT2  mothers 
were injected for four consecutive days between E15 and E18 with 
1 mg tamoxifen twice daily. Offspring were delivered by C-section 
at E20 and raised by foster mothers. For recombination analy-
sis in postnatal pups, lactating transgenic   mothers were injected 
intraperitoneally for ﬁ   ve consecutive days with either 1  mg 
tamoxifen twice daily (protocol 1), with 2 mg tamoxifen twice 
daily (protocol 2), with 3 mg tamoxifen twice daily   (protocol 3) 
or one single injection of 1 mg tamoxifen daily (protocol 4). 
R26RTPH2-CreERT2 litters from embryonal and postnatal tamoxifen 
injections were analyzed at P60 for β-gal expression as described 
below. All experimental procedures were approved by the Animal 
Welfare Committee (Regierungspräsidium Karlsruhe) and car-
ried out in accordance with the local Animal Welfare Act and the 
European Communities Council Directive of 24 November 1986 
(86/609/EEC).
X-GAL STAINING AND IMMUNOHISTOCHEMISTRY
Transgenic mice were characterized by X-Gal staining and dual-
label ﬂ  uorescent IHC. The following primary antibodies were 
used: rabbit α-TPH2 (kindly provided by Donald M. Kuhn, 
1:10000), chicken α-β-galactosidase (Abcam, 1:10000), rabbit 
α-GR (Santa Cruz Biotechnology, 1:1000) and mouse α-TPH1 
(Sigma, 1:500-2000) antibodies. The TPH1 antibody cross-reacts 
with TPH2 and detects both isoenzymes. Secondary antibodies 
were AF488 donkey α-rabbit (Invitrogen, 1:1000) and AF488 
donkey  α-mouse (Invitrogen, 1:200), AF555 donkey α-rabbit 
(Invitrogen, 1:1000), and Cy3 donkey α-chicken (Jackson 
ImmunoResearch, 1:1000). Sections were examined using a Nikon 
C1Si-CLEM  confocal laser-scanning microscope (Nikon Imaging 
Center, BioQuant, Heidelberg, Germany). Confocal image stacks 
for both   channels were acquired sequentially, and projected on 
average using ImageJ software. For the combinatorial ﬂ  uorescent 
expression in Brainbow1.0LTPH2-CreERT2 mice a Leica TCS SP5 X con-
focal laser-scanning microscope (Leica, Mannheim, Germany) was 
employed. For cyan ﬂ  uorescent protein (CFP) excitation a 458-nm 
argon line was used. Excitation of yellow ﬂ  uorescent protein (YFP) 
and RFP was performed with a white light laser at 512 and 565 nm, 
respectively. Confocal image stacks for all channels were acquired 
sequentially, and maximally projected using LAS AF Lite software. 
Confocal images were not processed with Adobe Photoshop to 
intensify colors and accentuate hues.
STATISTICAL METHODS
Coronal slices of two to four adult R26RTPH2-CreERT2 mice of each 
founder line were processed with dual-label ﬂ  uorescent IHC 
detecting βgal and TPH2. Image stacks of all slices that showed 
TPH2 staining were acquired using a confocal laser-scanning 
microscope. The ratio of βgal+/TPH2+ neurons to all TPH2+ 
neurons was calculated separately for caudal, median and dorsal 
raphe nuclei. Conﬁ  dence-bounds (CI) for recombination efﬁ  cacy 
and background recombination in adult mice were calculated 
using the Clopper–Pearson method based on signiﬁ  cance level 
95.0% (Clopper and Pearson, 1934). For adult R26RTPH2-CreERT2 
mice which had been injected during E15–18, P2–6 and P12–16 
(n = 3 each group) the ratio of βgal+/TPH2+ neurons to all TPH2+ 
neurons per group was expressed as the mean and as the range 
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RESULTS
GENERATION OF TPH2-CreERT2 TRANSGENIC MICE
We used the CreERT2/loxP-system which provides inducible, 
Cre-mediated recombination upon tamoxifen administration to 
generate transgenic mice which allow conditional manipulation 
of individual genes in serotonergic neurons at any desired time. 
Targeted spatial control in serotonergic neurons was achieved by 
using elements of the Tph2 locus as a promoter to control Cre 
expression. Since precise information about the regulatory elements 
which govern timely and 5-HT speciﬁ  c TPH2 expression is not 
available, we used a large genomic fragment of the Tph2 locus to 
drive CreERT2, thereby enhancing the probability to include most 
of the important regulatory components of Tph2. To this end, a 
P1-derived artiﬁ  cial chromosome (pPAC4) with a 177 kb genomic 
insert containing the entire Tph2 gene with large additional ﬂ  ank-
ing sequences (see Section “Materials and Methods”) was used to 
generate the TPH2-CreERT2 construct. The coding sequence of 
the CreERT2 fusion protein was inserted in place of the ATG-start 
of the Tph2 gene (Figure 1) by recombineering in bacteria (Lee 
et al., 2001). The modiﬁ  ed genomic fragment was released from the 
PAC backbone and ﬁ  nally introduced into the mouse germline of 
C57BL/6N by DNA microinjection. Five TPH2-CreERT2 founders 
were obtained (1.21, 1.23, 1.27, 1.35 and 1.38).
EFFICIENT AND SPECIFIC RECOMBINATION IN SEROTONERGIC 
NEURONS OF ADULT R26RTph2CreERT2 MICE
TPH2-CreERT2 founder were crossed to ROSA26 Cre reporter mice 
(R26R) (Soriano, 1999) to obtain R26RTph2CreERT2 mice. Temporal 
and spatial control of tamoxifen-induced CreERT2-mediated 
recombination in 5-HT neurons was determined and the efﬁ  cacy 
of serotonergic recombination in the caudal, dorsal and median 
raphe (MR) nuclei was calculated.
Adult R26RTph2CreERT2 mice were injected twice daily with either 
tamoxifen (1 mg) or vehicle for ﬁ  ve consecutive days. Animals 
were sacriﬁ  ced for analysis 5 days after the last tamoxifen injec-
tion. X-Gal staining of tamoxifen-treated R26RTph2CreERT2 mice from 
all lines revealed recombination in the brain stem and midbrain in 
regions shown to contain serotonergic somata (Figures 2A–I) while 
extraserotonergic brain regions showed no staining. Vehicle treated 
R26RTph2CreERT2 mice showed minimal background recombination 
among all lines (Figures 2J–L). TPH2-CreERT2 lines 1.21, 1.35 
and 1.38 showed the highest recombination efﬁ  ciency and lowest 
background recombination.
Next, we performed dual-label fluorescent IHC with 
anti-β-galactosidase (βgal) and anti-TPH2-antibodies to investigate 
selectivity and efﬁ  ciency of recombination in serotonergic neurons. 
While β-gal antibodies conﬁ  rm Cre-mediated recombination in the 
Rosa26 locus, TPH2 antibodies detect TPH2 which is the rate-limit-
ing enzyme in brain serotonin synthesis and solely found in seroton-
ergic raphe nuclei. As suggested by X-gal staining, recombination 
occurred exclusively in serotonergic neurons of all raphe nuclei with 
comparable efﬁ  ciency (Figures 3A–I). Vehicle treated mice showed 
only minimal background recombination (Figures 3J–L).
Lines 1.21 and 1.38 showed the highest recombination efﬁ  -
cacy in serotonergic neurons when tamoxifen was injected 
(91 and 90%, respectively) (Table S1 in Supplementary Material) 
while background recombination in vehicle treated mice was below 
2% (Table S2 in Supplementary Material). All further experiments 
were carried out with line 1.38.
RECOMBINATION IN SEROTONERGIC NEURONS OF R26RTPH2CreERT2 MICE 
DURING EMBRYOGENESIS AND POSTNATAL DEVELOPMENT
To investigate whether tamoxifen inducible recombination is also 
feasible during embryogenesis we injected pregnant mothers intra-
peritoneally with 1 mg tamoxifen twice daily for four consecutive 
days between E15 and E18. Offspring were delivered by C-section 
FIGURE 1 | TPH2-CreERT2 construct for DNA microinjection. 
A PCR-ampliﬁ  ed CreERT2.pA cassette ﬂ  anked by sequences (42 bp) 
homologous to the integration site of the PAC-based genomic Tph2 locus 
was recombineered in E. coli. CreERT2.pA was inserted into the ATG-start of 
Exon 1 of the mouse Tph2 gene.
FIGURE 2 | X-Gal staining of R26RTPH2-CreERT2 mice is restricted to the brain 
stem and midbrain where raphe nuclei are located. (A–C,J–L) Line 1.38. 
(D–F) Line 1.35. (G–I) Line 1.21. (A–I) Mice treated with tamoxifen (+Tx) (1 mg 
twice daily for 5 days) show abundant X-Gal staining at all levels of raphe nuclei. 
(J–L) Vehicle (+Ve) treated mice show nonsigniﬁ  cant X-Gal staining. (A,D,G,J) 
Median raphe nuclei; (B,E,H,K) dorsal raphe nuclei; (C,F,I,L) caudal raphe nuclei.Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 24  |  4
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on E20 since tamoxifen treatment impairs parturition (Boyle et al., 
2008; Erdmann et al., 2008). R26RTPH2-CreERT2 offspring were sacriﬁ  ced 
in adulthood and the efﬁ  cacy and selectivity of recombination ana-
lyzed with IHC against TPH2 and β-gal. Serotonergic recombination 
could be efﬁ  ciently induced with tamoxifen during embryogenesis 
(recombination efﬁ  cacy 66%) (Figures 4A–C; Figures S2A–C,J–L in 
Supplementary Material; Table S3 in Supplementary Material) but 
recombination rates were below those achieved during adulthood.
Next, we determined whether recombination during early and 
later postnatal development is feasible. Lactating mothers were 
injected intraperitoneally for ﬁ  ve consecutive days starting at P2 
and at P12, respectively. Different tamoxifen protocols were used: 
1 mg tamoxifen twice daily (protocol 1), 2 mg tamoxifen twice daily 
(protocol 2), 3 mg tamoxifen twice daily (protocol 3) and 1 mg 
tamoxifen once daily (protocol 4).
Intraperitoneal injections were well tolerated by lactating 
  mothers during the ﬁ  ve consecutive days of tamoxifen treat-
ment but mothers tended to abandon their offspring thereafter, 
in particular those treated with 2 mg × 2 mg tamoxifen during 
early  postnatal development (P2–6). Recombination during early 
and later postnatal development could be successfully induced 
in serotonergic neurons (Figures 4D–I; Figures S2D–I,M–R in 
Supplementary Material) but recombination efﬁ  ciency varied 
signiﬁ   cantly with protocols. Tamoxifen injections twice daily 
(2 mg ×  1  mg) led to superior recombination efﬁ  cacy  (68%) 
compared to single daily injections (1 mg × 1 mg) whereas dou-
bling the amount of tamoxifen (2 mg × 2 mg) during early post-
natal development (P2–6) did not result in better recombination 
efﬁ  cacy than with 2 mg × 1 mg tamoxifen per day. In contrast, 
further increasing the amount of tamoxifen (2 mg × 3 mg) in 
  lactating mothers with older offspring (P12–16) led to recombi-
nation efﬁ  cacies (72%) comparable to those achieved during early 
postnatal development with 2 mg × 1 mg tamoxifen (Table S3 in 
Supplementary Material).
In conclusion, signiﬁ  cant  recombination  efﬁ  cacies  could  be 
attained in R26RTPH2-CreERT2 offspring from tamoxifen injected preg-
nant or lactating mothers but recombination rates did not reach the 
level of adult recombination (90%). We also noted that insubstantial 
recombination occurred during embryogenesis and early postna-
tal development in regions which do not contain 5-HT neurons in 
adult mice. A few β-gal-positive/TPH2-negative cells were detected 
in the caudal and MR nuclei, the hypothalamus and deep layers of 
the cortex.
FIGURE 3 | Inducible recombination is restricted to serotonergic neurons 
of adult R26RTPH2-CreERT2 mice. R26RTPH2-CreERT2 mice of line 1.38 were injected 
with tamoxifen (1 mg twice daily) or vehicle for ﬁ  ve consecutive days starting 
at P90. Coronal sections show dual-label ﬂ  uorescence immunohistochemistry 
for TPH2 and β-gal in tamoxifen-treated (+Tx) (A–I) and vehicle-treated mice 
(+Ve) (J–L). (A,D,G,J) TPH2 ﬂ  uorescence; (B,E,H,K) β-gal ﬂ  uorescence; 
(C,F,I,L) Merged images. Colocalization is visualized at the level of caudal raphe 
(CR) nuclei (A-C), dorsal raphe (DR) nuclei (D-F,J-L) and median raphe nuclei 
(MR) (G-I) using confocal images. (C,F,I) In tamoxifen-treated mice there is 
extensive colocalization of β-gal and TPH2 indicating efﬁ  cient recombination. 
(J-L) Vehicle-treated mice show minimal colocalization demonstrating low 
background recombination without tamoxifen. Scale bars: 100 µm.
FIGURE 4 | Inducible recombination in serotonergic neurons of 
embryonal and postnatal R26RTPH2-CreERT2 mice. Pregnant or lactating 
mothers of line 1.38 were injected with tamoxifen (+Tx). (A–C) One milligram 
twice daily at E15–18; (D–F) 1 mg twice daily at P2-6; (G–I) 3 mg twice daily at 
P12-16. Transgenic R26RTPH2-CreERT2 offspring were sacriﬁ  ced at P60 and 
analyzed with dual-label ﬂ  uorescence immunohistochemistry for TPH2 and 
β-gal. Colocalization is visualized at the level of dorsal raphe nuclei using 
confocal images. (A,D,G) TPH2 ﬂ  uorescence; (B,E,H) β-gal ﬂ  uorescence; 
(C,F,I) merged images. Frequent colocalization of β-gal and TPH2 conﬁ  rms 
efﬁ  cient recombination during embryogenesis (C) and early (F) and later 
(I) postnatal development. Scale bars: 100 µm.Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 24  |  5
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INDUCIBLE RECOMBINATION IN BRAINBOW-1.0LTPH2-CreERT2 MICE 
RESULTS IN COMBINATORIAL EXPRESSION OF FLUORESCENT PROTEINS 
WITH MULTIPLE, DISTINCT COLORS IN 5-HT NEURONS
The recently described Brainbow-1.0L transgenic mouse line (Livet 
et al., 2007) allows individual ﬂ  uorescence labeling of living neu-
rons. In this line, Cre-mediated recombination of loxP-ﬂ  anked 
ﬂ  uorescence transgenes leads to a switch from RFP (red ﬂ  uorescent 
protein) expression to a stochastically determined combinatorial 
expression of CFP and YFP.
Double transgenic Brainbow-1.0LTPH2-CreERT2 mice were induced 
with 1 mg tamoxifen twice daily for one to ﬁ  ve consecutive days and 
recombination was analyzed by ﬂ  uorescence emission. Confocal 
laser-scanning microscopy of RFP, CFP and YFP ﬂ  uorescence 
detected the combinatorial expression of CFP and YFP leading 
to mosaic ﬂ  uorescent labeling of serotonergic neurons (Figure 5; 
Figure S3 in Supplementary Material). The length of tamoxifen 
treatment correlated with the proportion of recombined 5-HT neu-
rons. Three days of tamoxifen treatment were sufﬁ  cient to achieve 
maximal serotonergic recombination whereas in animals given 1–2 
days of tamoxifen treatment the proportion of recombined 5-HT 
neurons was signiﬁ  cantly reduced.
EFFICIENT KNOCKOUT OF THE GLUCOCORTICOID-RECEPTOR GENE IN 
SEROTONERGIC NEURONS OF ADULT GRﬂ  ox/GRﬂ  oxTPH2-CreERT2 MICE
Both R26R and Brainbow mice are reporter mice which express 
ﬂ  uorescent proteins or βgal following Cre-mediated recombina-
tion. To demonstrate that loxP ﬂ  anked target genes can also be 
efﬁ  ciently deleted in the adult serotonergic system we generated 
TPH2-CreERT2 mice that are homozygous for the loxP-ﬂ  anked 
glucocorticoid-receptor (GR) gene (GRﬂ  ox/GRﬂ  oxTPH2-CreERT2) 
(Tronche et al., 1999). The GR protein is ubiquitously expressed 
throughout the brain. In particular, 5-HT neurons show abun-
dant GR-antibody staining. Adult mice (2 months old) were treated 
with tamoxifen (1 mg twice daily for 5 days) and sacriﬁ  ced 14 days 
later. Double-immunostaining against GR and TPH revealed that 
80–90% of 5-HT neurons had lost their GR-immunoreactivity 
whereas GR expression was unchanged in all other brain regions 
examined (Figure 6; Figure S4 in Supplementary Material).
DISCUSSION
In this study, we describe a novel transgenic tool for conditional 
somatic manipulation of loxP-ﬂ  anked target genes in serotonergic 
neurons. Using the Tph2 genomic locus as a regulatory element to 
direct CreERT2 expression speciﬁ  cally to serotonergic neurons we 
show efﬁ  cient, tamoxifen-inducible recombination with minimal 
background activity in R26RTPH2-CreERT2 mice during development 
and adulthood.
Traditionally, transgenic mouse lines are generated via pronu-
clear injection of plasmid-derived DNA resulting in random inte-
gration of the transgene into the genome. The level and pattern of 
plasmid-derived transgene expression is determined both by the 
promotor and its integration site in the genome. Such transgenic 
mice show copy-number independent transgene expression in 
regions or cell types not associated with the original speciﬁ  city of 
the promoter (Bronson et al., 1996; Wallace et al., 2000; Chandler 
et al., 2007).
Because of the large insert size of BAC/PAC clones, they can 
often accommodate an entire gene of interest, including long-range 
cis-acting regulatory elements required for correct temporal and 
tissue-speciﬁ  c expression (Chandler et al., 2007). This is especially 
desirable for experiments where precise transgene expression is criti-
cal, such as for promotors driving Cre-recombinase (Lee et al., 2001). 
These large constructs allow copy-number dependent expression of 
the transgene resembling the expression of the endogenous gene 
independent of the integration site (Schedl et al., 1993; Casanova 
et al., 2001; Giraldo and Montoliu, 2001; Gong et al., 2003).
FIGURE 5 | Inducible recombination in adult Brainbow1.0LTPH2-CreERT2 mice 
leads to combinatorial expression of CFP and YFP in serotonergic neurons. 
Tamoxifen (+Tx) (1 mg twice daily) was injected for ﬁ  ve consecutive days 
starting at P90. (A,B) One week later, mice were sacriﬁ  ced and red, cyan and 
yellow ﬂ  uorescence emission was analyzed by confocal microscopy at the level 
of dorsal raphe nuclei. Stochastic recombination of loxP-ﬂ  anked ﬂ  uorescent 
genes leads to CFP and YFP expression. Depending on the ratio of CFP to YFP 
expression, each 5-HT neuron shows a distinct color ranging from dark blue 
(only CFP expression) to yellow (only YFP expression). (B) Fluorescence labeled 
neuronal projections are easily detectable. Scale bars: (A) 100 µm, (B) 20 µm.
FIGURE 6 | Inducible glucocorticoid receptor (GR) knockout in 
serotonergic neurons of adult GRﬂ  ox/GRﬂ  oxTPH2-CreERT2 mice. Tamoxifen 
(1 mg twice daily) or vehicle was injected for ﬁ  ve consecutive days starting at 
P60. Coronal sections show dual-label ﬂ  uorescence immunohistochemistry 
for TPH and GR in vehicle-treated (+Ve) (A–C) and tamoxifen-treated (+Tx) 
GRﬂ  ox/GRﬂ  oxTPH2-CreERT2 mice (D–F). Colocalization is visualized at the level of 
dorsal raphe nuclei using confocal images. (A,D) TPH ﬂ  uorescence; (B,E) GR 
ﬂ  uorescence; (C,F) merged images. (C) In vehicle-treated mice, GR 
colocalizes extensively with TPH. (F) GR is primarily expressed in TPH-negative 
neurons in tamoxifen-treated GR-knockout mice verifying the selective 
deletion of GR in 5-HT neurons. Scale bars: 100 µm.Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 24  |  6
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sections at E20. While behavioral effects of tamoxifen treatment 
have not been identiﬁ  ed in adult mice (Vogt et al., 2008) there 
is no comparable data on mice available that received tamoxifen 
treatment during development.
Taken together, Pet1-Cre mice are preferable if embryonal sero-
tonergic gene deletion starting at E12.5 (Scott et al., 2005) is desired 
as they do not require tamoxifen and convey high recombination 
rates. Inducible TPH2-CreERT2 mice are advantageous if recom-
bination is to start later than E12.5. As such, TPH2-CreERT2 mice 
are currently the only alternative for postnatal and adult induction 
of serotonergic recombination. Nonetheless, further research needs 
to be conducted to improve tamoxifen application during develop-
ment and to evaluate the biochemical, molecular and behavioral 
impact this treatment exerts on developing offspring.
Serotonergic recombination in Brainbow-1.0LTPH2-CreERT2 mice 
(Livet et al., 2007) creates a stochastic choice of Thy1-promotor 
controlled expression between two different loxP-ﬂ  anked ﬂ  uo-
rescence genes as a result of tandem integration of Brainbow-
1.0L copies. To date, it was unclear whether the Thy1-promotor 
is active in 5-HT neurons. Here we show that, upon tamoxifen 
induction, Brainbow-1.0LTPH2-CreERT2 mice display highly efﬁ  cient 
recombination in 5-HT neurons. Virtually all serotonergic neu-
rons can be labeled with combinatorial CFP and YFP expression. 
An advantage of the TPH2-CreERT2 system in conjunction with 
the Brainbow mice is the possibility of titrating the proportion of 
5-HT neurons exhibiting recombination by reducing the duration 
of tamoxifen treatment. This should facilitate anterograde trac-
ing experiments of single, distinctly color-labeled serotonergic 
cell projections by three-dimensional reconstruction from serial 
sections which will help to deﬁ  ne the connectivity of individual 
5-HT neurons or its cell clusters (B1-9) with other brain regions 
and within the raphe nuclei.
Tissue-speciﬁ  c recombination efﬁ  cacies derived from artiﬁ  -
cial Cre reporter lines should be interpreted carefully regarding 
their value to predict recombination frequencies for loxP-ﬂ  anked 
target genes (Weber et al., 2001). On this account, we substanti-
ated our results obtained with R26R Cre reporter and Brainbow 
mice by inducing a selective knockout of the endogenous GR 
gene exclusively in 5-HT neurons of the adult mouse. With the 
GRﬂ  ox/GRﬂ  oxTPH2-CreERT2 mice it will be possible to decipher the 
reciprocal interactions between the HPA axis and 5-HT neurons, 
systems that have been implicated together in the etiology of sev-
eral pathological conditions like escalated aggression and violence 
or anxiety and depression (Haller et al., 2005; Miczek et al., 2007; 
Lanfumey et al., 2008).
The neurotransmitter serotonin plays a diverse and important 
role in both the developing and adult brain (Gaspar et al., 2003). 
With our TPH2-CreERT2 line we provide a tool for highly efﬁ  cient 
and inducible recombination speciﬁ  cally in the serotonergic system. 
This system will allow the study of the roles of many genes in the 
regulation of serotonin systems and hence its role in brain devel-
opment and function. Moreover, the possibility of manipulating 
gene expression selectively in mature serotonergic neurons allows 
direct molecular and behavioral effects of candidate gene deletion 
to be distinguished from compensatory, homeostatic mechanisms 
during development. In the pathology of complex neuropsychiatric 
diseases, serotonergic genes, in conjunction with stressors, may act at 
In this study we were able to demonstrate that tissue-  speciﬁ  c 
regulatory elements of the mouse Tph2 locus, present on a 177 kb 
genomic DNA fragment and comprising the entire Tph2 gene 
plus large ﬂ  anking regions, reliably direct Cre expression selec-
tively to serotonergic neurons in all ﬁ   ve analyzed transgenic 
TPH2-CreERT2 lines.
To date only two mouse lines published have been shown to 
target loxP-ﬂ  anked gene knockouts to the serotonergic system. 
A knockin of the Cre recombinase into the Sert gene has been 
used to achieve recombination in serotonergic neurons (Zhuang 
et al., 2005). However, this strategy is compromised by the fact 
that it results in a hemizygous Sert knockout. Furthermore, SERT 
is expressed in extraserotonergic neurons during development 
(Gaspar et al., 2003). Therefore, using the endogenous Sert locus 
to control Cre expression will lead to developmental recombination 
in neurons outside the serotonergic system. Finally, the Sert-Cre 
mouse line does not contain regulatory elements that allow tem-
poral control of Cre-mediated recombination.
Recently, a Pet1-Cre transgenic mouse line was published (Scott 
et al., 2005) in which cell-type speciﬁ  c serotonergic gene inactiva-
tion of loxP-ﬂ  anked target genes will be irrevocably initiated at 
E12.5 during embryogenesis. Despite its excellent characteristics 
to create tissue-speciﬁ  c embryonal knockouts in the serotoner-
gic system, Pet1-Cre lacks the possibility of temporal control. As 
Pet-1 is a key player in a transcriptional mechanism that controls 
embryonal 5-HT neuron differentiation (Hendricks et al., 2003) it 
would be of interest whether its regulatory elements are sufﬁ  cient to 
achieve inducible CreERT2-mediated gene inactivation in the entire 
serotonergic system of the postnatal and adult brain as well.
TPH2 is the rate-limiting enzyme of 5-HT synthesis in the 
serotonergic raphe nuclei (Walther et al., 2003). In the brain, it is 
strongly and exclusively expressed in serotonergic neurons start-
ing during embryogenesis around E11 and continuing throughout 
adult life (Cote et al., 2003, 2007). Thus, regulatory elements of 
the Tph2 locus should ensure strong serotonergic Cre expression 
in TPH2-CreERT2 mice at any time from embryogenesis to adult-
hood. To test this, we induced recombination in R26RTPH2-CreERT2 
mice during embryogenesis, postnatal development and adulthood. 
In adult mice, tamoxifen injections twice daily for ﬁ  ve consecutive 
days lead to highly efﬁ  cient induction of recombination speciﬁ  -
cally in serotonergic neurons. During embryogenesis and postna-
tal development intraperitoneal injections to the mothers led to 
efﬁ  cient serotonergic recombination (66–72%) in their offspring 
but rates were inferior to adult recombination (90%). This ﬁ  nding 
is most likely a result of the tamoxifen application route rather 
than of attenuated activity of Tph2 regulatory sequences driving 
CreERT2 during development as expression of TPH2 commences 
already at E11. Moreover, we used the identical Tph2 regulatory 
sequences to direct the expression of other genes to serotonergic 
neurons during development and found strong expression already 
at E15 (unpublished observation). In our opinion, these results 
demonstrate that ip application to the mother does not lead to suf-
ﬁ  cient tamoxifen concentrations in their offspring to achieve high 
recombination rates. Furthermore, tamoxifen is an active substance 
which inhibits ERs and stimulates progesterone receptors. In preg-
nant mice, tamoxifen treatment inhibits parturition (Boyle et al., 
2008; Erdmann et al., 2008) which necessitated scheduled cesarean Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 24  |  7
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